---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016809"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T07:37:17.311009+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q2 fiscal 2025 revenue up 6.1% to $13.9M, net income $0.6M

## Summary
- Revenue $13.9M vs $13.1M YoY; nine-month revenue $40.2M (+6.9%).
- Operating income $0.7M vs $0.4M; nine-month operating income $1.4M vs loss $0.2M.
- Net income $0.02 EPS vs $0.01; nine-month net income $1.0M ($0.03 EPS) vs loss $0.2M.
- Two largest customers in contract manufacturing represented 83% of total revenue in nine-month period.
- Co-CEOs cite customer base expansion and revenue growth from core business.

## SEC filing metadata
- accession: 0001437749-25-016809
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774925016809/0001437749-25-016809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774925016809/inbp20250417_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016809
- JSON: https://secwatch.observer/filing/0001437749-25-016809.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.